By reimagining clinical trials as the initial step in designing a service ecosystem, organizations can accelerate time to delivery and lay the groundwork for successful commercialization. The post Building Service Infrastructure for “Made-To-Order” Therapies appeared first on MedCity News.
The longer we delay, the further we shift costs from polluters to patients — and to every taxpayer who funds Medicare, Medicaid and community hospitals. Environmental stewardship and human health are inseparable; regulating microplastics is preventive medicine on a national scale. The post Microplastics Are in Our Blood — Why Aren’t Federal Regulators Acting? appeared…
The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Obsidian Therapeutics aims to show its TIL cell therapy has advantages over an Iovance Biotherapeutics TIL therapy marketed for treating melanoma. Obsidian’s merger with Galera Therapeutics will give it a public listing and a private placement to support clinical development of the combined company’s cancer drug pipeline. The post Obsidian, Galera Merger Comes With $350M…
Himanshu Shah, an activist investor and large shareholder of Novavax, whose stock has plummeted over the years, believes the company should cut costs more aggressively, reduce the size of its board, and do more to prop up its financial performance. But are the criticisms valid? The post Is Shah Capital’s Criticism of Novavax Fair? A…
Insmed’s Brinsupri is the first drug specifically approved for treating non-cystic fibrosis bronchiectasis, a progressive and potentially fatal lung disorder. The drug, licensed from AstraZeneca, inhibits activation of neutrophils, white blood cells that play a role in inflammatory and immune responses. The post Chronic Lung Disease in Medical Literature for More Than 200 Years Finally…
Medicare beneficiaries will have 32 Medicare Advantage plans with prescription drug coverage available to choose from, on average, in 2026.
Nearly half (47%) of metropolitan areas across the country had only one or two hospitals or health systems providing general inpatient hospital care in 2022, a new KFF analysis finds. The analysis examines the extent of competition among hospitals amid a wave of hospital consolidation that has drawn the attention of state and federal regulators.…More
Sionna Therapeutics found strong investor interest in its cystic fibrosis drugs, which could rival blockbuster Vertex Pharmaceuticals product Trikafta. The biotech has three internally developed programs that hit a target unaddressed by any currently available CF therapies. The post Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline appeared first on…
The introduction of consumer-facing health AI should be understood less as a clinical breakthrough and more as a cultural one. Patients now expect their health information to be as accessible and navigable as their banking or travel data. That expectation will reshape how health systems design digital experiences and how vendors think about patient engagement….